Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | -.--% | -.--% | -68.28% |
Apr. 24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
Apr. 19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 15.64M 11.48M |
---|---|---|---|---|---|
Net income 2024 * | -19M -13.94M | Net income 2025 * | -15M -11.01M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.8
x | P/E ratio 2025 * |
-1.02
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.46% |
3 months | -69.27% | ||
6 months | -60.14% | ||
Current year | -68.28% |
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.49M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- ATE Stock